摘要:
Compounds having the formula are angiogenesis inhibitors. Also disclosed are compositions containing the compounds, methods of making the compounds, and methods of treatment using the compounds.
摘要:
Compounds having the formula are angiogenesis inhibitors. Also disclosed are compositions containing the compounds, methods of making the compounds, and methods of treatment using the compounds.
摘要:
Compounds having the formula are angiogenesis inhibitors. Also disclosed are compositions containing the compounds, methods of making the compounds, and methods of treatment using the compounds.
摘要:
Disclosed are 3'-N-desmethyl-3'-N-susbstituted-6-O-methyl-11-deoxy-11,12-cyclic carbamate erythrolide A derivatives which are antagonists of luteinizing hormone-releasing hormone (LHRH). Also disclosed are pharmaceutical compositions comprising the compounds, to methods of using the compounds and to the process of making the same.
摘要:
Compounds of formula (SEQ ID NO:2) and (SEQ ID NO:3), which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compositions comprising these compounds, methods of treatment using these compounds, and methods of inhibiting angiogenesis.
摘要翻译:描述了可用于治疗由血管生成引起或加重的病症的式(SEQ ID NO:2)和(SEQ ID NO:3)的化合物。 还公开了包含这些化合物的药物组合物,使用这些化合物的治疗方法,以及抑制血管发生的方法。
摘要:
Compounds of formula (SEQ ID NO:1), which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compositions comprising these compounds, methods of treatment using these compounds, and methods of inhibiting angiogenesis.
摘要翻译:描述了可用于治疗由血管生成引起或加剧的病症的式(SEQ ID NO:1)的化合物。 还公开了包含这些化合物的药物组合物,使用这些化合物的治疗方法,以及抑制血管发生的方法。
摘要:
Peptides having the formula: A0-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10 wherein A0 is selected from hydrogen or an acyl group; A10 is a hydroxyl group or an amino acid amide; and A1, A2, A3, A4, A5, A6, A7, A8, and A9 are amino acyl residues as defined herein.
摘要翻译:具有以下结构式的肽:<?in-line-formula description =“In-line Formulas”end =“lead”?> A 1 sub> > 2 sub> 3→3→3→3→5→ - →3→ > 7 u> -A i> i> i> i> u> “end =”tail“?>其中A 选自氢或酰基; A 10是羟基或氨基酸酰胺; 和A 1,A 2,A 3,A 4,A 5, A 6,A 7,A 8和A 9是如本文所定义的氨基酰基残基。
摘要:
Compounds having the formula (SEQ ID NO: 1), which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compositions comprising these compounds, methods of treatment using these compounds, and methods of inhibiting angiogenesis.
摘要翻译:描述了可用于治疗由血管发生引起或加剧的病症的具有式(SEQ ID NO:1)的化合物。 还公开了包含这些化合物的药物组合物,使用这些化合物的治疗方法,以及抑制血管发生的方法。
摘要:
Compounds of formula (SEQ ID NO:1), which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compositions comprising these compounds, methods of treatment using these compounds, and methods of inhibiting angiogenesis.
摘要翻译:描述了可用于治疗由血管生成引起或加剧的病症的式(SEQ ID NO:1)的化合物。 还公开了包含这些化合物的药物组合物,使用这些化合物的治疗方法,以及抑制血管发生的方法。
摘要:
Tetrahydroisoquinoline derivatives of the formula: ##STR1## or a pharmaceutically acceptable salt, ester, or prodrug thereof, having activity as an LHRH antagonist, as well as pharmaceutical compositions containing the same, and methods for their use and preparation.